Medivate Partners
Finance · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
15f Kwangil Seocho Gu Plz 331, Seoul, 06...Phone Number
+82 25360704Website
www.medivatepartners.comRevenue
$6.6 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
2
1
About Medivate Partners
Medivate, is a private equity and venture capital firm that focuses investment in biotech/healthcare industry in Asia and North America. The firm is well positioned to capture surging healthcare investment opportunities between Asia and North America, and looks to arbitrage the unique cross border investment advantages. While closing its third fund, Medivate Partners quickly built a reputation for providing inner circle access to top caliber syndicates and successful life science deals in Asia and North America.Explore more
Medivate Partners Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Medivate Partners your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Medivate Partners had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Medivate Partners recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Medivate Partners has recently received funding, and reach out quickly before it becomes old news!
Medivate Partners, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Medivate Partners has new funding data
Product Launch: Get notified when Medivate Partners launches new products
Check out if Medivate Partners is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Medivate Partners
Recommended Actions
Reach out to Masked Content who joined Medivate Partners as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Medivate Partners is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Medivate Partners is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Medivate Partners.
Medivate Partners Tech Stack
A closer look at the technologies used by Medivate Partners
Medivate Partners News & Media
Cognate BioServices closes Series B and completes acquisition of Cobra Biologics
/PRNewswire/ -- Cognate BioServices, a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy...Cognate BioServices closes Series B and completes acquisition of Cobra Biologics
Venture capital news. Updated daily. VC deal news, fund news, transition news, industry news.Cognate acquires Cobra Biologics
Cognate BioServices has acquired UK and Sweden-based Cobra Biologics, an advanced therapy CDMO that specializes in providing manufacturing services for the plasmid DNA and viral vector. No financial terms were disclosed. Cognate's backers include EW Healthcare Partners.Cognate BioServices announces acquisition of Cobra Biologics
-Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products -EW Healthcare Partners and its co-investors provide the financing for the transaction MEMPHIS, Tenn., Nov. 4, 2019 /PRNewswire/ -- Cognate...
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Medivate Partners
Sign Up For FreeTo access detailed company insights
Medivate, is a private equity and venture capital firm that focuses investment in biotech/healthcare industry in Asia and North America. The firm is well positioned to capture surging healthcare investment opportunities between Asia and North America, and looks to arbitrage the unique cross border investment advantages. While closing its third fund... Read More
